AMA Asks HHS to Rescind Its Peptide Compounding Policy as Public Comments Close on November 13
At its Interim Meeting in Orlando, the American Medical Association adopted policy urging HHS and the FDA to "immediately rescind" directives that ease compounding of unapproved synthetic peptides, and to pursue enforcement against compounding pharmacies, telehealth platforms, and online sellers. AMA board member Ilse Levin said patients face "serious, preventable harm." HHS's comment period on its policy covering BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500 closed at the end of November 13, with 115 comments posted on Regulations.gov by that day.